• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

意大利透析方式的成本分析。

Cost analysis of dialysis modalities in Italy.

作者信息

Tediosi F, Bertolini G, Parazzini F, Mecca G, Garattini L

机构信息

Mario Negri Institute for Pharmacological Research, Ranica, Italy.

出版信息

Health Serv Manage Res. 2001 Feb;14(1):9-17. doi: 10.1177/095148480101400102.

DOI:10.1177/095148480101400102
PMID:11246787
Abstract

This study analyses management and costs of dialysis in the Italian National Health Service (NHS). Information on efficacy and health-related quality of life (HRQOL) based on the existing literature also is presented. The clinical differences between the dialysis modalities seem to be related to their appropriateness to specific patient groups. Efficacy rates are similar and the only differences are in complications and HRQOL. Traditional haemodialysis (THD) can be done by Italian patients in dialysis centres or in hospital. Highflux haemodialysis (HFHD) is generally only done in hospital. Peritoneal dialysis (PD) is usually done at home. The cost analysis was performed on a sample of Italian dialysis centres and hospitals, according to the full cost method. As expected, HFHD was more expensive than THD and PD, but no marked differences emerged among the different HFHD modalities. THD modalities in dialysis centres were less costly than in hospitals. Automated PD (APD) was much more expensive (almost twice) than continuous ambulatory PD (CAPD), the cheapest method in absolute terms. This study confirms that dialysis is costly and that it is very difficult to assess the cost-effectiveness of the different approaches. Although this study has limits, it should provide sufficient analytical information to local healthcare managers for more rational allocation of financial resources to dialysis services.

摘要

本研究分析了意大利国家医疗服务体系(NHS)中透析的管理与成本。同时,还基于现有文献介绍了有关疗效及健康相关生活质量(HRQOL)的信息。透析方式之间的临床差异似乎与其对特定患者群体的适用性有关。疗效率相似,唯一的差异在于并发症和健康相关生活质量。传统血液透析(THD)可由意大利患者在透析中心或医院进行。高通量血液透析(HFHD)通常仅在医院进行。腹膜透析(PD)通常在家中进行。根据完全成本法,对意大利透析中心和医院的样本进行了成本分析。正如预期的那样,高通量血液透析比传统血液透析和腹膜透析更昂贵,但不同的高通量血液透析方式之间未出现明显差异。透析中心的传统血液透析方式比在医院成本更低。自动化腹膜透析(APD)比持续性非卧床腹膜透析(CAPD)贵得多(几乎两倍),而持续性非卧床腹膜透析是绝对成本最低的方法。本研究证实透析成本高昂,且很难评估不同方法的成本效益。尽管本研究存在局限性,但它应为地方医疗管理者提供足够的分析信息,以便更合理地分配用于透析服务的财政资源。

相似文献

1
Cost analysis of dialysis modalities in Italy.意大利透析方式的成本分析。
Health Serv Manage Res. 2001 Feb;14(1):9-17. doi: 10.1177/095148480101400102.
2
The cost of renal dialysis in a UK setting--a multicentre study.英国环境下肾透析的成本——一项多中心研究。
Nephrol Dial Transplant. 2008 Jun;23(6):1982-9. doi: 10.1093/ndt/gfm870. Epub 2008 Jan 3.
3
Health economic evaluations: the special case of end-stage renal disease treatment.卫生经济评估:终末期肾病治疗的特殊情况
Med Decis Making. 2002 Sep-Oct;22(5):417-30. doi: 10.1177/027298902236927.
4
Economic evaluation of centre haemodialysis and continuous ambulatory peritoneal dialysis in Ministry of Health hospitals, Malaysia.马来西亚卫生部医院中心血液透析与持续性非卧床腹膜透析的经济学评估
Nephrology (Carlton). 2005 Feb;10(1):25-32. doi: 10.1111/j.1440-1797.2005.00360.x.
5
Comparison of cost-utility between automated peritoneal dialysis and continuous ambulatory peritoneal dialysis.自动化腹膜透析与持续不卧床腹膜透析的成本-效用比较。
Arch Med Res. 2013 Nov;44(8):655-61. doi: 10.1016/j.arcmed.2013.10.017. Epub 2013 Nov 8.
6
Cost analysis of dialysis treatments for end-stage renal disease (ESRD).终末期肾病(ESRD)透析治疗的成本分析。
Clin Invest Med. 1995 Dec;18(6):455-64.
7
Cost-effectiveness of haemodialysis and peritoneal dialysis for patients with end-stage renal disease in Singapore.新加坡终末期肾病患者血液透析和腹膜透析的成本效益
Nephrology (Carlton). 2016 Aug;21(8):669-77. doi: 10.1111/nep.12668.
8
The economic cost of dialysis: a comparison between peritoneal dialysis and in-center hemodialysis in a Spanish unit.透析的经济成本:西班牙一家医疗机构中腹膜透析与中心血液透析的比较
Adv Perit Dial. 1996;12:93-6.
9
Healthcare systems and end-stage renal disease (ESRD) therapies--an international review: costs and reimbursement/funding of ESRD therapies.医疗保健系统与终末期肾病(ESRD)治疗——一项国际综述:ESRD治疗的成本及报销/资金情况
Nephrol Dial Transplant. 1999;14 Suppl 6:31-41. doi: 10.1093/ndt/14.suppl_6.31.
10
A cost effectiveness analysis of the treatment of end stage renal failure.终末期肾衰竭治疗的成本效益分析
N Z Med J. 1990 Apr 25;103(888):171-4.

引用本文的文献

1
The Impact of Chronic Kidney Disease on Nutritional Status and Its Possible Relation with Oral Diseases.慢性肾脏病对营养状况的影响及其与口腔疾病的可能关系。
Nutrients. 2022 May 10;14(10):2002. doi: 10.3390/nu14102002.
2
Three years evaluation of peritoneal dialysis and hemodialysis absorption costing: perspective of the service provider compared to funds transfers from the public and private healthcare systems.腹膜透析和血液透析吸收成本的三年评估:服务提供者视角与公共和私人医疗保健系统资金转移的比较。
J Bras Nefrol. 2022 Apr-Jun;44(2):204-214. doi: 10.1590/2175-8239-JBN-2021-0118.
3
A comprehensive approach to assess the costs of renal replacement therapy for end-stage renal disease in France: the importance of age, diabetes status, and clinical events.
评估法国终末期肾病肾脏替代治疗成本的综合方法:年龄、糖尿病状态和临床事件的重要性
Eur J Health Econ. 2017 May;18(4):459-469. doi: 10.1007/s10198-016-0801-6. Epub 2016 May 5.
4
Renal replacement therapy for autosomal dominant polycystic kidney disease (ADPKD) in Europe: prevalence and survival--an analysis of data from the ERA-EDTA Registry.欧洲常染色体显性多囊肾病(ADPKD)的肾脏替代治疗:患病率与生存率——来自欧洲肾脏协会-欧洲透析与移植协会(ERA-EDTA)注册中心的数据分析
Nephrol Dial Transplant. 2014 Sep;29 Suppl 4(Suppl 4):iv15-25. doi: 10.1093/ndt/gfu017.
5
Economic evaluation of end stage renal disease patients undergoing hemodialysis.接受血液透析的终末期肾病患者的经济评估。
J Pharm Bioallied Sci. 2012 Apr;4(2):107-11. doi: 10.4103/0975-7406.94810.
6
The costs in provision of haemodialysis in a developing country: a multi-centered study.发展中国家血液透析提供的成本:一项多中心研究。
BMC Nephrol. 2011 Sep 6;12:42. doi: 10.1186/1471-2369-12-42.